Editas Medicine Suspends At-The-Market Equity Offering Program

On May 26, 2026, Editas Medicine, Inc. notified TD Securities (USA) LLC (TD Cowen) that it is suspending and terminating the prospectus supplement dated March 21, 2025, effectively pausing its "at-the-market" (ATM) equity offering program. While the underlying Sales Agreement originally entered into on May 14, 2021 (and subsequently amended) remains in effect, the company will not sell any additional shares of common stock under this program until a new prospectus or prospectus supplement is filed and becomes effective. As of the suspension date, Editas Medicine had issued and sold a total of 14,327,365 shares through the ATM program, generating aggregate gross proceeds of approximately $43.9 million before commissions and expenses. This move halts the company's current ability to raise capital through periodic open-market stock sales under the existing filing.